文献速递结核与非结核分枝杆菌

移民前潜伏性结核筛查的成本效果分析

Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries.
PubMed 文献 · Emerg Infect Dis · 2019-01-01

该研究采用离散事件模拟,评估赴低发病率国家移民在移民前进行潜伏性结核感染(LTBI)筛查并配合到达后随访治疗的成本效果。确定性分析中,移民前γ干扰素释放试验筛查加到达后利福平治疗为优选策略,并计算了不同结核发病率来源国移民的每质量调整生命年增量成本。结果为移民前LTBI筛查的成本效果提供了证据。

要点

  • 移民前LTBI筛查联合到达后治疗在确定性分析中具成本效果优势。
  • 优选方案为移民前γ干扰素释放试验筛查加到达后利福平治疗。
  • 成本效果因来源国结核发病率不同而异。

核心结论

  • 移民前LTBI筛查对赴低发病率国家移民具有成本效果。

研究设计与样本

  • 采用离散事件模拟,评估强制和赞助的移民前LTBI筛查联合到达后随访治疗。

主要发现

  • 确定性分析中,移民前γ干扰素释放试验筛查加到达后利福平治疗为优选策略。
  • 计算了来自不同结核发病率国家移民的每质量调整生命年增量成本。

临床怎么用

  • 结果可结合可持续性、可接受性和项目实施研究,为政策决策提供参考。

局限性

  • 需进一步研究可持续性、可接受性和项目实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prospective migrants to countries where the incidence of tuberculosis (TB) is low (low-incidence countries) receive TB screening; however, screening for latent TB infection (LTBI) before immigration is rare. We evaluated the cost-effectiveness of mandated and sponsored preimmigration LTBI screening for migrants to low-incidence countries. We used discrete event simulation to model preimmigration LTBI screening coupled with postarrival follow-up and treatment for those who test positive. Preimmigration interferon-gamma release assay screening and postarrival rifampin treatment was preferred in deterministic analysis. We calculated cost per quality-adjusted life-year gained for migrants from countries with different TB incidences. Our analysis provides evidence of the cost-effectiveness of preimmigration LTBI screening for migrants to low-incidence countries. Coupled with research on sustainability, acceptability, and program implementation, these results can inform policy decisions.

来源:Emerg Infect Dis,查看原文。版权归原作者所有。

引用

  1. Campbell JR, Johnston JC, Cook VJ, et al. Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries. Emerg Infect Dis. 2019. PMID: 30882302. doi:10.3201/eid2504.171630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。